| HOME >> BIOLOGY >> TECHNOLOGY |
2008 2007
(unaudited)
Current assets:
Cash and cash equivalents $19,239,265 $40,582,643
Restricted cash 5,000,000 -
Short-term investments 6,415,735 12,153,945
Accounts receivable 6,562,753 5,245,763
Prepaid expenses 1,068,407 476,511
Other current assets 254,197 15,783
Total current assets 38,540,357 58,474,645
Long term restricted cash 15,000,000 -
Property and equipment, net 6,288,751 6,571,024
Patents, net 1,221,809 1,312,991
Other long term assets 183,588 183,588
Deferred costs 988,650 68,884
Total assets $62,223,155 $66,611,132
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable $1,434,184 $1,393,664
Accrued expenses and other liabilities 4,296,922 3,602,886
Current portion of long term debt 4,000,000 4,000,000
Total current liabilities 9,731,106 8,996,550
Other long term liabilities 376,501 374,040
Long term debt 15,994,706 16,668,458
Total liabilities 26,102,313 26,039,048
Stockholders' equity:
Common stock, $0.0001 par
value; 100,000,000 shares
authorized; 22,138,723 and
22,0
'/>"/>
| SOURCE PharmAthene, Inc. Copyright©2008 PR Newswire. All rights reserved |